Corporate News     08-Sep-21
Caplin Steriles receives USFDA approval for Labetalol Hydrochloride Injection
Caplin Steriles, a subsidiary of Caplin Point Laboratories, has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Labetalol Hydrochloride Injection USP, 100 mg/20 mL (5 mg/mL) and 200 mg/40 mL (5 mg/mL) Multiple-dose Vials, a generic therapeutic equivalent version of (RLD), TRANDATE Injection, of Sebela Ireland.

Labetalol Hydrochloride Injection USP is indicated for control of blood pressure in severe hypertension. According to IQVIATM (IMS Health), Labetalol hydrochloride Injection had US sales data of approximately $6 million for the 12-month period ending June 2021.

Previous News
  Caplin Point Laboratories consolidated net profit rises 18.57% in the December 2024 quarter
 ( Results - Announcements 07-Feb-25   17:34 )
  Caplin Point Laboratories to discuss results
 ( Corporate News - 15-May-23   10:23 )
  Caplin Point Laboratories standalone net profit declines 9.56% in the September 2018 quarter
 ( Results - Announcements 03-Nov-18   08:18 )
  Caplin Steriles receives USFDA approval for Phenylephrine hydrochloride Ophthalmic solution
 ( Corporate News - 24-May-24   12:26 )
  Caplin Point Laboratories consolidated net profit rises 34.20% in the June 2019 quarter
 ( Results - Announcements 13-Aug-19   16:02 )
  Caplin Steriles receives USFDA approval for Labetalol Hydrochloride Injection
 ( Corporate News - 08-Sep-21   12:59 )
  Caplin Point Laboratories consolidated net profit rises 22.40% in the September 2018 quarter
 ( Results - Announcements 03-Nov-18   08:18 )
  Caplin Point Laboratories standalone net profit rises 44.55% in the March 2017 quarter
 ( Results - Announcements 11-May-17   13:55 )
  Caplin Point Laboratories standalone net profit declines 1.15% in the March 2018 quarter
 ( Results - Announcements 29-May-18   17:59 )
  Caplin Point Laboratories to hold board meeting
 ( Corporate News - 01-Feb-25   10:02 )
  Caplin Point Laboratories receives USFDA approval for Levetiracetam in Sodium Chloride Injection
 ( Corporate News - 17-Jan-25   15:19 )
Other Stories
  Board of Procter & Gamble Health recommends interim dividend
  12-Feb-25   16:37
  Board of AVT Natural Products recommends interim dividend
  12-Feb-25   16:31
  Board of ASM Technologies recommends interim dividend
  12-Feb-25   16:29
  Aveer Foods to conduct EGM
  12-Feb-25   16:27
  Getalong Enterprise to hold EGM
  12-Feb-25   16:27
  Dhruva Capital Services schedules EGM
  12-Feb-25   16:27
  Privi Speciality Chemicals director resigns
  12-Feb-25   15:59
  Zen Technologies signs MoU with TXT Group at Aero India 2025
  12-Feb-25   15:56
  Karur Vysya Bank appoints Sankar Balabhadrapatruni as Executive Director
  12-Feb-25   15:54
  Board of Ashok Leyland approves investment of up to Rs 700 cr in subsidiaries
  12-Feb-25   15:52
Back Top